COMMUNIQUÉ DE PRESSE publié le 18/01/2024 à 22:50, il y a 8 mois 1 jour CORRECTION BY SOURCE: Solta Medical's Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China Bausch Health Companies Inc. and Solta Medical have announced the approval of Thermage® FLX and the TR-4 Return Pad by China's National Medical Products Administration (NMPA), marking a significant milestone for Solta Medical and opening up significant opportunities in the Chinese market. The approval represents a substantial achievement for the R&D and Regulatory Teams, signifying continued growth for the Thermage technology. The non-invasive treatment, which uses radiofrequency technology to tighten and improve the texture of the skin, has seen over two million treatments globally and is now set to continue its growth in China. The approval paves the way for delivering proven technology to the Chinese market and signifies a crucial breakthrough in the medical aesthetics market. Thermage FLX NMPA Approval Medical Aesthetics Market TR-4 Return Pad China
COMMUNIQUÉ DE PRESSE publié le 18/01/2024 à 14:00, il y a 8 mois 1 jour Solta Medical’s Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China Bausch Health Companies Inc. and Solta Medical announce the approval of Thermage® FLX and the TR-4 Return Pad by China's National Medical Products Administration (NMPA). This approval represents a significant breakthrough in one of the largest medical aesthetics markets, allowing the companies to continue the momentum of the growth of Thermage in China. The non-invasive treatment, Thermage, is a versatile and effective technology that can be used on all skin types and genders, delivering exceptional results for patients. For more information, visit www.bauschhealth.com and www.solta.com. Thermage FLX NMPA Approval Medical Aesthetics Market Non-invasive Treatment Bausch Health Companies
COMMUNIQUÉ DE PRESSE publié le 08/01/2024 à 06:00, il y a 8 mois 11 jours Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute Bausch Health Companies Inc. and its gastroenterology business Salix Pharmaceuticals presented oral arguments at the U.S. Court of Appeals for the Federal Circuit regarding the matter of Salix Pharmaceuticals, LTD et al v. Norwich Pharmaceuticals, Inc. No ruling was issued following the oral arguments. The company continues to advocate for the safety of patients benefiting from XIFAXAN® (rifaximin) 550 mg tablets, indicated for hepatic encephalopathy recurrence and irritable bowel syndrome with diarrhea. Salix Pharmaceuticals focuses on the prevention and treatment of gastrointestinal diseases for over 30 years and markets its products to U.S. health care providers. On the other hand, Bausch Health Companies Inc. is a global diversified pharmaceutical company with a mission to improve people's lives through various health care products, primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, and eye health. The news release contains forward-looking statements about Bausch Health's future performance and the appeal with respect to intellectual property. The actual results are subject to certain risks and uncertainties. For more information, visit www.bauschhealth.com and connect with them on Twitter and LinkedIn. Bausch Health Companies Inc. Salix Pharmaceuticals Gastrointestinal Diseases XIFAXAN Oral Arguments
COMMUNIQUÉ DE PRESSE publié le 21/12/2023 à 13:00, il y a 8 mois 29 jours Bausch Health Announces Positive Topline Results From Global Phase 2 Study Evaluating Amiselimod (an S1P antagonist) to Treat Ulcerative Colitis
COMMUNIQUÉ DE PRESSE publié le 18/12/2023 à 14:00, il y a 9 mois 1 jour DUOBRII(TM) Lotion to Treat Moderate to Severe Plaque Psoriasis Now Available Through Quebec’s Public Drug Plan
COMMUNIQUÉ DE PRESSE publié le 18/12/2023 à 14:00, il y a 9 mois 1 jour La lotion DUOBRII(MC) pour le traitement du psoriasis en plaques modéré ou sévère maintenant couverte par le régime public d’assurance médicaments du Québec
COMMUNIQUÉ DE PRESSE publié le 05/12/2023 à 14:00, il y a 9 mois 14 jours Salix in Collaboration with The U.S. Pain Foundation and the International Foundation for Gastrointestinal Disorders Establish the Inaugural Opioid-Induced Constipation (OIC) Awareness Day Salix Pharmaceuticals, Bausch Health Companies Inc., U.S. Pain Foundation, and IFFGD collaborate to establish the first annual Opioid-Induced Constipation (OIC) Awareness Day to raise awareness about the often-overlooked side effect of opioids and provide a platform for patients, caregivers, and healthcare providers to discuss and address OIC Healthcare Providers Chronic Pain Opioid-Induced Constipation Awareness Day Patient Advocacy
COMMUNIQUÉ DE PRESSE publié le 10/11/2023 à 14:00, il y a 10 mois 9 jours The Absence of an Overt Hepatic Encephalopathy (OHE)-Specific Diagnosis Code May Result in Increased OHE-Related Length of Stay and Hospitalization-Related Costs Due to OHE Rate Underestimation, According to New Analysis
COMMUNIQUÉ DE PRESSE publié le 10/11/2023 à 06:00, il y a 10 mois 9 jours CORRECTION BY SOURCE: The Absence of an Overt Hepatic Encephalopathy (OHE)-Specific Diagnosis Code May Result in Increased OHE-Related Length of Stay and Hospitalization-Related Costs Due to OHE Rate Underestimation, According to New Analysis
COMMUNIQUÉ DE PRESSE publié le 08/11/2023 à 14:00, il y a 10 mois 11 jours As Daylight Saving Time Comes to a Close, Bausch Health Champions Mental Health with a Spotlight on Preventing Seasonal Affective Disorder (SAD)
Publié le 19/09/2024 à 17:45, il y a 11 heures 17 minutes Gimv draagt helft van participatie in Infravest over aan WorxInvest (communicatie in toepassing van artikel 7:97 WVV)
Publié le 19/09/2024 à 17:45, il y a 11 heures 17 minutes Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)
Publié le 19/09/2024 à 17:45, il y a 11 heures 17 minutes Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)
Publié le 20/09/2024 à 02:00, il y a 3 heures 2 minutes Academy of Math and Science Celebrates Hispanic Heritage Month
Publié le 19/09/2024 à 23:15, il y a 5 heures 47 minutes Cypher Metaverse Inc. Announces Second Closing of Financing
Publié le 19/09/2024 à 23:00, il y a 6 heures 2 minutes WestJet Partners with FLYHT and NOAA to Improve Weather Forecasting in North America
Publié le 19/09/2024 à 23:00, il y a 6 heures 2 minutes Cerrado Files NI 43-101 Preliminary Economic Assessment Technical Report and Mineral Resource Estimate for The Minera Don Nicolas Mine in Santa Cruz, Argentina
Publié le 19/09/2024 à 21:09, il y a 7 heures 52 minutes EQS-Adhoc: Mercedes-Benz Group AG adjusts full-year guidance for the year 2024 based on current market outlook
Publié le 19/09/2024 à 18:44, il y a 10 heures 17 minutes Fuller, Smith & Turner PLC: Transaction in own shares
Publié le 19/09/2024 à 18:03, il y a 10 heures 59 minutes Funding Circle Plc: POS-Transaction in Own Shares
Publié le 19/09/2024 à 17:52, il y a 11 heures 9 minutes PILOT 28 : FIGEAC AÉRO remporte 3 nouveaux contrats sur l'A320 pour 65 millions d'euros
Publié le 19/09/2024 à 17:52, il y a 11 heures 9 minutes PILOT 28: FIGEAC AÉRO secures 3 new wins on the A320 airframe for 65 million euros